Critical Contrast: Aclarion (ACON) & Its Rivals

Aclarion (NASDAQ:ACON) is one of 93 publicly-traded companies in the “Medical Services” industry, but how does it compare to its peers? We will compare Aclarion to similar companies based on the strength of its earnings, dividends, risk, valuation, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Aclarion and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,908.50%	-67.53%	-63.01%
Aclarion Competitors	-902.09%	-91.82%	-14.52%

Insider & Institutional Ownership

7.5% of Aclarion shares are held by institutional investors. Comparatively, 58.1% of shares of all “Medical Services” companies are held by institutional investors. 0.8% of Aclarion shares are held by insiders. Comparatively, 13.2% of shares of all “Medical Services” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Aclarion and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Aclarion	$50,000.00	-$6.99 million	0.00
Aclarion Competitors	$9.89 billion	$239.88 million	11.97

Aclarion’s peers have higher revenue and earnings than Aclarion. Aclarion is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Aclarion and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	1	1	0	0	1.50
Aclarion Competitors	625	2491	5121	184	2.58

Aclarion presently has a consensus target price of $11,758.50, indicating a potential upside of 190,784.74%. As a group, “Medical Services” companies have a potential upside of 15.45%. Given Aclarion’s higher possible upside, research analysts clearly believe Aclarion is more favorable than its peers.

Risk and Volatility

Aclarion has a beta of 1.42, suggesting that its stock price is 42% more volatile than the S&P 500. Comparatively, Aclarion’s peers have a beta of 1.53, suggesting that their average stock price is 53% more volatile than the S&P 500.

Summary

Aclarion peers beat Aclarion on 11 of the 13 factors compared.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.